Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks lecorb, great site stock ref. I keep in eye am market may jump in back.
AMERICAN BULLS:STAY LONG,LAST PATTERN:BEARISH HARAMI
Signal Update
Our system’s recommendation today is to STAY LONG. The previous BUY signal was issued on 05/14/2015, 13 days ago, when the stock price was 1,7530. Since then ONTY has risen by +91,67%.
Market Outlook
Candlesticks warned us today to be on alert with a new bearish pattern. Market attention is now on the downside.more...
https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=ONTY
Glad to see you got out. Way too much downside coming imo
Thanks for FYI...,
Cool!!!
Pay close attention to CERE
Ceres Sprouts Off Patent Awarded For Soybean Seed Enhancement
2:53 pm ET May 27, 2015 (Benzinga)
Joel Elconin is the co-host of Benzinga's #PreMarket Prep, a daily trading idea radio show.
Ceres Inc (NASDAQ: CERE) shares are trading higher by $1.46 at $3.14 in Wednesday's session. The catalyst for the doubling of the agricultural biotechnology company is U.S. patent awarded for a genetic sequence derived from soybean, covering uses of the gene in areas such as research, product development and plant transformation.
The low-priced volatile issue spiked to the $4 level for the fifth time since March 4, but has not been able to sustain that level for more than one session. That is the case in Wednesday's session as Ceres spike from its low for the day ($1.77) to $4 on the heels of the announcement before retreating to its current level.
It should be noted that other spikes in the issue took place on average volume.
However, the current rally is taking place on much higher than average volume, as 12.3M shares have changed hands compared with its 20-day average of 1M shares with two hours remaining in the session.
Again, thanks iam out@3.60 and save. couple k. So now iam waiting and see whatever.
Oh, thanks... I need to do some chart studying...
ONTY:Markit short selling activity, It is increasing from low to médium.
ONTY must come down to find your balance in the chart. RSI(14)82.28
I'm pretty new to this what does all that mean?...
$3.60 +3.15% Short sellers, attack again RSI(14)83.10 Overbought
Turning point in fall $1.93/2.00
http://stockcharts.com/h-sc/ui?s=ONTY&p=D&b=5&g=0&id=p26099102557&a=264845671
Push push...
Too much downside pressure the gap up wants to fill back down
thanks bud - GL to you as well - have a great night -
Thanks o nice analysis GLTU always
$ONTY Chart – Riding the upper Bollinger Band @ 3.15 & EMA 4 @ 2.99 support – they are the 1st Key levels to hold – EMA 8 @ 2.64 is the 3rd support level – as long as the middle Bollinger Band @ 1.95 support level holds the up trend should continue –
There is a GAP between HoD(high of day) on the 21st & LoD(low of day) on the 22nd – keep an EYE on it – Fast Sto & RSI are both in the overbought/power zone – Fast Sto @ 96.97 is nearly maxed – not a lot of juice to run higher – monster volume bars the last 2 trading days – the MACD Line trajectory is starting to get steep –
Yep and it almost hit a 52 week high in AH trading , will be watching close in the am take care
Thanks 4 advice
Tough to speculate , yet watch PM trading first thing, although that can be tricky also take profits always and GLTU !!!
How will u think tomorrow guess!
And going higher in AH trading GLTA !!!!
P&D Just look at KBIO -> ONTY IS NEXT
Biotech P&D's are a disgrace time to get out before this baby burns.
Only would go there if it breaks 3,5$...but rsi is already at 80..i say we go lower..
Thanks Ospreyeye! Like to see us move above the 200 DMA next week. Nice move in AH.
Good to see you here Kei. You are all over these biotech stocks.
I'm trading this, but have a core position in another account. Looks like this will gather more upside volume over next six sessions.
$ONTY Weekly Chart - very nice 3 week run - tested the 200 Day Moving Average @ 3.45 this week, but failed to close above - as this chart shows the 200 DMA is the Key level to close above & turn into support - a close above the 200 DMA would be bullish - candles above the 200 DMA on the weekly chart = more upside potential - fail to break the 200 DMA w/ a close above for the week = downside risk -
Fast Sto is hitting the 80 power/overbought zone - RSI @ 73.93 & in the "power" / overbought zone -the MACD Line is positive & pointing north - 3.00 & 2.50 are 2 support levels to hold on a pullback - the 100 DMA @ 2.16 & the 50 DMA @ 2.07 are Key levels to hold & turn into support on an extended pullback -
going up with volume after-hour...based on today's huge volume and ASCO presentation is very close, i expect big gapper open on tuesday
* * $ONTY Video Chart 05-22-15 * *
Link to Video - click here to watch the technical chart video
ONTY $$$$ Nice jump today! Is it to late to join the party?
ASCO is next week >> Oncothyreon’s abstract presentation in the upcoming meeting of American Society of Clinical Oncology (ASCO) in Chicago, runs from May 29 to June 2, 2015.
Maybe next week but not today..going lower..
Nice finds. I already have ONTY and AVEO. Just added the other two just now thanks! Nice airline gapper btw with oil crashing down
Nice find Crude
$ONTY Golden cross shaping up on the daily!!?
Rolling into a stellar ASCO. Could be glorious!
GLTA
Huge jump on initial stage testing. Same story new ticker. Sell off incoming, you heard it here first.
The biopharmaceutical company, Oncothyreon Inc (USA) (NASDAQ:ONTY) stock soared 31.19%, and experienced approximately 18 times increment in its trading volume as of 12:02 PM EDT. Currently the stock is trading at $2.75, with a volume of 18.28 million. Traditionally, the stock changes hands with a trading volume of 1.20 million.
The increase in the stock price and volume is largely driven by investors hunger to get a stake in the company following Oncothyreon’s submission of an abstract for presentation in the upcoming meeting of American Society of Clinical Oncology (ASCO) in Chicago, starting from May 29 to June 2, 2015. Moreover, the investors are excessively eager to buy the stock on the news of positive study results; though the study is at its initial stage.
Why was there a jump? News letter promo?
All I see is posting in caps i.e. pumping lol.
I hope...or I did a heck of a lot of posting for nothing.
Followers
|
61
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
792
|
Created
|
05/16/06
|
Type
|
Free
|
Moderators |
company web-site - http://www.oncothyreon.com
recent event / CC - http://ir.oncothyreon.com/events.cfm -
Oncothyreon is a biotechnology company dedicated to the development of oncology products that can improve the lives and outcomes of cancer patients. We are currently developing multiple therapeutic candidates designed to target cancer in specific and effective ways. Our pipeline includes both synthetic vaccines and small molecules for a variety of cancer indications. Oncothyreon is headquartered in Bellevue, Washington. The Company is traded on the NASDAQ National Market under the symbol ONTY and on the Toronto Stock Exchange under the symbol ONY. We are The Cancer Vaccine People(TM).
Stimuvax
ONTY's drug Stimuvax, in partnership with Merck KGaa, is now in large Phase 3 Pivotal Trial program for NSCLC:
Phase III NSCLC (Lung) "START" Trial - http://www.clinicaltrials.gov/ct2/show/NCT00409188
Phase III NSCLC "INSPIRE" Trial (Asia) - http://www.clinicaltrials.gov/ct2/show/NCT01015443
Phase II NSCLC w/Avastin Trial - http://www.clinicaltrials.gov/ct2/show/NCT00828009
Phase I/II NSCLC Trial in Japan - http://www.clinicaltrials.gov/ct2/show/NCT00960115
Phase IV Long-Term Safety Trial - http://www.clinicaltrials.gov/ct2/show/NCT01423760
Phase II HDPC Trial - http://bethesdatrials.cancer.gov/clinical-research/search_detail.aspx?ProtocolID=NCI-11-C-0247
Pipe-Line - http://www.oncothyreon.com/pipeline/overview.html
Remaining Pipe-Line -
ONT-10 - http://www.oncothyreon.com/pipeline/vaccines/ONT-10/overview.html
PX-866 - http://www.oncothyreon.com/pipeline/small/PX-866/overview.html
Start of Trial with Taxotere - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=526661
Start of Trial with Erbitux - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=537953
PRESS RELEASES
Oncothyreon Initiates Phase 2 Trial of its PI-3 Kinase Inhibitor PX-866 in Patients with Glioblastoma - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=561867
Oncothyreon Presents Preclinical Data for ONT-10 and PX-866 at American Association for Cancer Research - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=561521
Oncothyreon Announces Publication of Safety & Survival Data From Stimuvax Phase 1/2 NSCLC Trial - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=515788
Oncothyreon Initiates Phase 1/2 Trial of its PI-3 Kinase Inhibitor PX-866 in Combination with Cetuximab - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=537953
Oncothyreon announces that Merck Serono is resuming the Stimuvax clinical program in lung cancer - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=480296
Oncothyreon announces temporary suspension of Stimuvax clinical trials - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=453976
Oncothyreon announces STRIDE Phase 3 BC trial - June 22, 2009 http://investorshub.advfn.com/boards/read_msg.aspx?message_id=38926533
Oncothyreon announces clinical data at ASCO - May 30, 2009 - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=38259984
Oncothyreon announces development plans - Dec. 18, 2008 - http://biom.client.shareholder.com/releasedetail.cfm?ReleaseID=355043
Merck KGaA buys manufacturing rights for Stimuvax - Dec. 18, 2008 - http://biom.client.shareholder.com/releasedetail.cfm?ReleaseID=355037
ONTY/Merck KGaA amend agreements - Aug 8, 2007http://www.marketwatch.com/news/story/biomira-merck-kgaa-sign-amended/story.aspx?guid=%7B43FD62A1%2D....
MEDICAL PRESENTATIONS
ASCO 2007 Stimuvax Abstract - http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=32165
"16 pts were evaluated for this interim safety analysis ..........As of September 2006, 10 pts were still on study treatment."
ASCO 2008 Stimuvax Abstract - http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34755
"The 2-year survival rate of 64% ....compares favorably with previously reported survival for chemoradiation in stage III NSCLC."
ASCO 2009 Stimuvax Abstract - http://www.abstract.asco.org/AbstView_65_31704.html
"a remarkable # of pts received prolonged treatment...16 pts received L-BLP25 for 2.0-7.7 years, 10 pts were treated for >5 years."
COMPLETE MEDICAL PAPERS
Paper summarizing all Stimuvax trials to date - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39761211
Publication of Data From Phase 1/2 NSCLC Trial - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=515788
A Peptide Vaccine Strategy in NSCLC - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39627241
Phase IIb Trial in NSCLC Stage IIIB and IV - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39099793
"The greatest difference in survival was observed in stage IIIB LR patients (adjusted HR = 0.524; 95% CI, 0.261 to 1.052; P = .069)"
- Fig 3. Overall survival by study arm - http://jco.ascopubs.org/cgi/content-nw/full/23/27/6674/F3
- Fig 4. Survival analysis for stage IIIB with MFE or stage IV patients - http://jco.ascopubs.org/cgi/content-nw/full/23/27/6674/F4
- Fig 5. Survival analysis for stage IIIB locoregional patients - http://jco.ascopubs.org/cgi/content-nw/full/23/27/6674/F5
Detailed Description of START Trial - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39062424
First Interim Look - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58060227
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |